Eben Tessari Sells 138,614 Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Stock

Key Points

• Eben Tessari, COO of Kiniksa Pharmaceuticals, sold 138,614 shares on August 5th for nearly $4.6 million, reducing his ownership by 73.52% to 49,915 shares.
• Kiniksa Pharmaceuticals reported earnings of $0.23 per share for the last quarter, exceeding analyst expectations of $0.18, with revenues of $156.80 million.
• Equities analysts have expressed optimism about Kiniksa's stock, with upgrades from Jefferies and Wells Fargo, now setting price targets as high as $54.00.

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) COO Eben Tessari sold 138,614 shares of the company's stock in a transaction that occurred on Tuesday, August 5th. The stock was sold at an average price of $33.20, for a total value of $4,601,984.80. Following the sale, the chief operating officer directly owned 49,915 shares in the company, valued at $1,657,178. This trade represents a 73.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Eben Tessari also recently made the following trade(s):

• On Monday, July 14th, Eben Tessari sold 18,900 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $28.72, for a total value of $542,808.00.
• On Monday, June 16th, Eben Tessari sold 17,300 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $28.28, for a total value of $489,244.00.
• On Wednesday, June 11th, Eben Tessari sold 45,042 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $30.51, for a total value of $1,374,231.42.
• On Monday, June 9th, Eben Tessari sold 10,319 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $30.38, for a total value of $313,491.22.
• On Tuesday, June 10th, Eben Tessari sold 15,506 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $30.46, for a total value of $472,312.76.
• On Monday, May 19th, Eben Tessari sold 12,000 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $26.41, for a total value of $316,920.00.

Kiniksa Pharmaceuticals International Trading Up 1.2%

Shares of KNSA traded up $0.39 during midday trading on Thursday, reaching $33.11. 606,877 shares of the stock were exchanged, compared to its average volume of 702,245. Kiniksa Pharmaceuticals International, plc has a 52 week low of $17.82 and a 52 week high of $33.98. The company's 50 day moving average is $28.74 and its two-hundred day moving average is $24.36. The company has a market capitalization of $2.42 billion, a P/E ratio of 827.96 and a beta of 0.14.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last issued its quarterly earnings data on Tuesday, July 29th. The company reported $0.23 earnings per share for the quarter, beating analysts' consensus estimates of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a return on equity of 1.05% and a net margin of 0.90%. The company had revenue of $156.80 million for the quarter, compared to the consensus estimate of $145.21 million. On average, sell-side analysts expect that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have commented on KNSA shares. Jefferies Financial Group upped their price objective on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a "buy" rating in a research report on Tuesday, July 29th. Wells Fargo & Company upped their price objective on Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the company an "overweight" rating in a research report on Wednesday, July 9th. Wall Street Zen raised Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 2nd. Finally, Wedbush reissued an "outperform" rating and set a $36.00 price target on shares of Kiniksa Pharmaceuticals International in a research report on Monday, July 21st. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $41.17.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

Several institutional investors have recently added to or reduced their stakes in KNSA. Corebridge Financial Inc. raised its stake in shares of Kiniksa Pharmaceuticals International by 3.6% in the first quarter. Corebridge Financial Inc. now owns 15,979 shares of the company's stock worth $355,000 after purchasing an additional 549 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of Kiniksa Pharmaceuticals International by 84.8% in the first quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock worth $27,000 after purchasing an additional 568 shares during the last quarter. Sound View Wealth Advisors Group LLC raised its position in Kiniksa Pharmaceuticals International by 4.0% during the first quarter. Sound View Wealth Advisors Group LLC now owns 14,657 shares of the company's stock valued at $326,000 after acquiring an additional 568 shares in the last quarter. Martingale Asset Management L P raised its position in Kiniksa Pharmaceuticals International by 1.3% during the first quarter. Martingale Asset Management L P now owns 50,000 shares of the company's stock valued at $1,111,000 after acquiring an additional 640 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Kiniksa Pharmaceuticals International by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,843 shares of the company's stock valued at $507,000 after acquiring an additional 1,002 shares in the last quarter. Institutional investors and hedge funds own 53.95% of the company's stock.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.